2-氯甲基-4-呋喃甲酸甲酯 | 20416-07-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 呋喃
• 中文名称: 2-氯甲基-4-呋喃甲酸甲酯
• 中文别名: 5-(氯甲基)呋喃-3-羧酸甲酯
• 英文名称: methyl 5-(chloromethyl)furan-3-carboxylate
• 英文别名: Methyl-5-chlormethyl-3-furoat
• CAS: 20416-07-3
• 化学式: C₇H₇ClO₃
• mdl: MFCD15144234
• 分子量: 174.584
• InChiKey: MKTBDDIZMVUFDS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.285
• 拓扑面积：
  39.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-氯甲基-4-呋喃甲酸甲酯 在 ion exchanger in H(+) form 、 potassium carbonate 、 N,N-二甲基甲酰胺 作用下， 以 甲醇 、 水 、 丙酮 、 甲苯 为溶剂， 反应 36.0h， 生成 5-{(Z)-3-[(1S,2S,3S,5R)-3,5-Dihydroxy-2-((E)-(R)-3-hydroxy-oct-1-enyl)-cyclopentyl]-propenyl}-furan-3-carboxylic acid methyl ester
  参考文献：
  名称：

  Synthetic Analogues of Prostaglandins F2α and E2

  摘要：

  从[3aα，4α，5β，6aα] -（±）-六氢-5-羟基-4-（（E）-（3α）-羟基-1-辛烯基）-2H-环戊[b]呋喃-2-酮（Ia）和[3aα，4α，5β，6aα] -（±）-六氢-5-羟基-4- [4-（3-氯苯氧）-（3α）-羟基-1-丁烯基]环戊[b]呋喃-2-酮（Ib）开始，合成了含有呋喃或噻吩核的上链的前列腺素F2α和E2的新衍生物XIIa，b - XVa，b和XXa，b - XXIIIa，b。通过保护羟基，随后还原和与磷酸铵盐IV-VII制备的ylide进行Wittig反应，并最终去保护（或氧化加去保护），将二醇Ia和Ib转化为上述的前列腺素F2α和E2的类似物。

  DOI：

  10.1135/cccc19940138

文献信息

• [EN] COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS<br/>[FR] COMPOSÉS ET MÉTHODES DE TRAITEMENT D'INFECTIONS BACTÉRIENNES
  申请人：UNIV NEW YORK

  公开号：WO2019232083A1

  公开（公告）日：2019-12-05

  This invention relates to compounds, pharmaceutical compositions comprising them, and methods of using the compounds and compositions for treating bacterial infections. This invention relates more particularly to compounds and pharmaceutical compositions thereof, methods of inhibiting H2S-producing enzymes with the compounds, and methods of treating bacterial infections with the compounds.

  这项发明涉及化合物，包括它们的药物组合物，以及使用这些化合物和组合物治疗细菌感染的方法。这项发明更具体地涉及化合物和其药物组合物，使用这些化合物抑制H2S产生酶的方法，以及使用这些化合物治疗细菌感染的方法。
• KINASE INHIBITORS
  申请人：Respivert Limited

  公开号：US20170291917A1

  公开（公告）日：2017-10-12

  There are provided compounds of formula I, wherein T, A, Q, Z, G, R 4 , R 5a , R 5b and n have meanings given in the description, which compounds have antiinflammatory activity (e.g. through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.

  提供了化合物I的公式，其中T、A、Q、Z、G、R4、R5a、R5b和n的含义如描述中所示，这些化合物具有抗炎活性（例如，通过抑制p38丝裂原活化蛋白激酶酶家族中的一个或多个成员；Syk激酶；以及酪氨酸激酶Src家族的成员之一）并且在治疗中有用，包括在药物组合中，特别是用于治疗炎症性疾病，包括肺部、眼睛和肠道的炎症性疾病。
• Kinase inhibitors
  申请人：Respivert Limited

  公开号：US10072034B2

  公开（公告）日：2018-09-11

  There are provided compounds of formula I, wherein T, A, Q, Z, G, R4, R5a, R5b and n have meanings given in the description, which compounds have antiinflammatory activity (e.g. through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.

  提供了式 I 的化合物、 其中 T、A、Q、Z、G、R4、R5a、R5b 和 n 具有描述中给出的含义，这些化合物具有抗炎活性（例如，通过抑制以下成员中的一种或多种：p38 丝裂原活化蛋白激酶家族；Syk 激酶；以及酪氨酸激酶 Src 家族成员），可用于治疗，包括药物组合，特别是用于治疗炎症性疾病，包括肺、眼和肠道的炎症性疾病。
• Compounds and Methods for Treating Bacterial Infections
  申请人：NEW YORK UNIVERSITY

  公开号：US20210214359A1

  公开（公告）日：2021-07-15

  This invention relates to compounds, pharmaceutical compositions comprising them, and methods of using the compounds and compositions for treating bacterial infections. This invention relates more particularly to compounds and pharmaceutical compositions thereof, methods of inhibiting H 2 S-producing enzymes with the compounds, and methods of treating bacterial infections with the compounds.
• [EN] KINASE INHIBITORS<br/>[FR] INHIBITEURS DE KINASE
  申请人：RESPIVERT LTD

  公开号：WO2017174995A1

  公开（公告）日：2017-10-12

  There are provided compounds of formula I, (I) wherein T, A, Q, Z, G, R4, R5a, R5b and n have meanings given in the description, which compounds have antiinflammatory activity (e.g. through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.